Shay Capital’s C4 Therapeutics CCCC Stock Holding History

Shay Capital’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-420,000	Closed	-$932K	–	506
2025 Q3	$932K	Buy	+420,000	New	+$1.01M	0.08%	184
2025 Q2	–	Sell	-93,413	Closed	-$149K	–	337
2025 Q1	$149K	Buy	+93,413	New	+$279K	0.02%	257
2024 Q1	–	Sell	-10,000	Closed	-$56.5K	–	390
2023 Q4	$56.5K	Buy	+10,000	New	+$22.8K	0.01%	249
2022 Q2	–	Sell	-10,000	Closed	-$243K	–	456
2022 Q1	$243K	Sell	10,000 -5,000	-33%	-$121K	0.03%	349
2021 Q4	$483K	Sell	15,000 -22,500	-60%	-$890K	0.08%	189
2021 Q3	$1.68M	Buy	+37,500	New	+$1.61M	0.22%	101

Other funds holding CCCC

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Shay Capital's CCCC Position: Q4 2025 in Review

Shay Capital sold out of C4 Therapeutics (CCCC) in Q4 2025, closing a stake of 420,000 shares — an estimated $932K sold.

Shay Capital first reported a position in CCCC in Q3 2021 and held it in 6 quarters. The position peaked at $1.68M in Q3 2021. 101 funds tracked by Wall St. Rank hold CCCC as of Q4 2025.

Shay Capital reported no remaining C4 Therapeutics position as of Q4 2025 after selling out during the quarter.
Shay Capital sold 420,000 C4 Therapeutics shares in Q4 2025, an estimated $932K.
Shay Capital first reported a position in C4 Therapeutics in Q3 2021 and held it in 6 quarters.
Shay Capital's C4 Therapeutics position peaked at $1.68M in Q3 2021.
101 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2025.

Based on Shay Capital's 13F filing for Q4 2025, filed 17 Feb 2026.